UO Medicina Legale Ausl Piacenza, Piacenza, Italy.
IRCCS Orthopedic Institute Galeazzi, Milan, Italy.
Acta Biomed. 2022 May 11;93(2):e2022186. doi: 10.23750/abm.v93i2.13008.
To the Editor, The ongoing rise of New Psychoactive Substances (NPS), i.e. psychotropic molecules devised and synthesized to replicate the effects of traditional drugs of abuse in order to circumvent banned substances schedules, has been posing a challenge of enormous magnitude to substance detection systems and law enforcement worldwide. Still, it would be remiss to ignore the role played by the unprecedented public health emergency relating to the COVID-19 pandemic in the exacerbation of the NPS crisis. The diversion of resources has in fact hindered conventional approaches to drug monitoring, surveillance, control, and public health responses. The dangerous path ahead in our struggle against NPS abuse is best exemplified by the rather recent emergence of isotonitazene, an analogue of a benzimidazole class of analgesic compounds, powerful synthetic opioid and full mu-opioid receptor agonist belonging to the 2-benzylbenzimidazole group of compounds, which comprises the structurally different clonitazene, metonitazene and etonitazene (1). Isonitazene has reportedly been detected on European markets in at least five different forms and could even supplant fentanyl derivatives (2). Currently available data on isonitazene-related abuse and fatalities seem to be emblematic of the volatile, elusive nature of NPS: deaths in which isotonitazene was involved in fact presented substantial differences from casualties arising from synthetic opioids abuse. Case reports have highlighted how flualprazolam was detected in most fatalities associated with isotonitazene whereas flualprazolam was involved in only 8% of other synthetic opioid overdose deaths (3). Rather than rising background use, such a finding seems to suggest likely co-use or co-distribution of flualprazolam and isotonitazene. The key element of polysubstance involvement is rife in synthetic opioid overdose deaths. That being said, significantly more substances were implicated in isotonitazene-related deaths than fatalities linked to other synthetic opioid overdose (4, 5). Such dynamics and mortality patterns further stress the urgency of expanding health services for those suffering from opioid addiction disorders. Fine-tuned and standardized detection mechanisms relying on specialized assays based on sensitive instrumentation are essential for the timely and accurate characterization of such novel synthetic opioids (6-8). Isotonitazene in fact cannot be detected by common fentanyl testing strips (9). Hence, the essential nature of clinical and toxicological cannot be overstated, if we are to effectively deal with the public health risks arising from new substances or classes, along with the healthcare and social costs thereof (10). As new substances appear on illicit markets and are detected, their distinctive traits can only be identified by user experience, in the early stages (11-13). Nonetheless, the pandemic scenario has brought about a profound alteration of substance abuse patterns, and opened up new avenues of supply and demand for which our surveillance/detection systems may not be fully prepared or well-suited. As the pandemic appears to recede and hopefully turn into an endemic context based on coexistence with the SARS-CoV-2 and its less harmful variants, it would be a mistake to take for granted that drug abuse/trafficking dynamics will also get back to where they were before the pandemic. Putting in place policies aimed at monitoring web-based platforms and social media can potentially constitute a valuable tool in terms of keeping in check emerging substances, given how during the COVID-19 pandemic many interactions between traffickers and buyers have moved online (14). After all, social media have been playing an increasingly relevant role as interacting platforms, which users and drug dealers can take advantage of in order to discuss drug prices, substance purity, distinctive traits of the "high" (i.e. desired drug effects) they are seeking, ways of taking the substances, dosages, and characteristics of any new NPS becoming available on such back-alley marketing channels (15). Softwares designed and specifically programmed to sift through and analyze all detectable online information in that regard may prove valuable to figure out evolving dynamics of trafficking, purchases and use. Probing social media users has proven effective tool for public health concerns, e.g. drug checking services which have been harnessed due to their harm reduction potential in places estimated to be at risk, with large crowds gathering (concerts, clubs and the like). Nonetheless, research efforts need to be directed towards the new realm of criminality, the "Dark Web", in which all sorts of illegal exchanges and interactions are known to take place. A 2020 study has highlighted the appalling risks for drug users who choose to pursue that option in order to buy drugs (16). Three dealers were selected on a specific "Dark Web" marketplace, and NPS were ordered through such a channel. All these exchanges were thoroughly documented, and an analysis was undertaken of all the substances thus bought, totaling nine samples, by NMR, HRMS, LC-UV, and two also by x-ray diffraction. It was ultimately concluded that four out of five substances bought had been labeled with NPS names that did not match the actual substance, and two out of three samples of substances sold as new (i.e. unscheduled) NPS were instead found to be already documented substances, mislabeled and peddled under false pretenses. Drug dealers were therefore either deceiving their clients or were unaware as to the actual substances which they were selling. In light of such extremely worrisome findings, it is not hard to understand the implications and the major public health risks that such new trends of trafficking and abuse may entail. It is therefore incumbent upon the scientific community and law enforcement agencies to adapt and strive to meet the new challenges brought by the new criminal ecosystems in terms of drug enforcement, first and foremost the impervious environment known as "Dark Web" relying on untraceable cryptocurrencies for illegal transactions.
致编辑,新精神活性物质(NPS)的持续兴起,即设计和合成的精神活性分子,旨在复制传统滥用药物的效果,以规避被禁止物质的时间表,这对全球物质检测系统和执法部门构成了巨大挑战。然而,忽视与 COVID-19 大流行相关的前所未有的公共卫生紧急情况在加剧 NPS 危机方面所起的作用将是草率的。事实上,资源的转移阻碍了对药物监测、监测、控制和公共卫生应对的常规方法。我们与 NPS 滥用作斗争的危险道路最好的例证是,一种名为异托那嗪的新出现的物质,它是一种苯并咪唑类镇痛化合物的类似物,是一种强大的合成阿片类药物和完全的 μ-阿片受体激动剂,属于 2-苄基苯并咪唑类化合物,其中包括结构不同的氯硝西泮、甲硝西泮和依替西泮(1)。据报道,异托那嗪已在欧洲市场上以至少五种不同形式出现,甚至可能取代芬太尼衍生物(2)。目前关于异托那嗪相关滥用和死亡的数据似乎是 NPS 多变、难以捉摸性质的典型代表:实际上,涉及异托那嗪的死亡与合成阿片类药物滥用造成的伤亡存在显著差异。病例报告强调了在与异托那嗪相关的大多数死亡中如何检测到氟拉西泮,而氟拉西泮仅涉及其他合成阿片类药物过量死亡的 8%(3)。这种发现似乎表明可能存在氟拉西泮和异托那嗪的共同使用或共同分布,而不是背景使用率的上升。在合成阿片类药物过量死亡中,这种多物质参与的关键因素很普遍。也就是说,与其他合成阿片类药物过量死亡相比,与异托那嗪相关的死亡涉及的物质明显更多(4、5)。这种动态和死亡模式进一步强调了扩大对阿片类药物成瘾障碍患者的健康服务的紧迫性。依赖于基于敏感仪器的专门分析的精细和标准化检测机制对于及时和准确地描述此类新型合成阿片类药物至关重要(6-8)。异托那嗪实际上不能通过常见的芬太尼检测条检测到(9)。因此,如果我们要有效应对新物质或类别的公共卫生风险,以及随之而来的医疗保健和社会成本,临床和毒理学的重要性怎么强调都不为过(10)。随着新物质出现在非法市场并被检测到,只有在早期阶段(11-13),通过用户体验才能识别它们的独特特征。尽管如此,大流行情景带来了物质滥用模式的深刻变化,并为供应和需求开辟了新的途径,我们的监测/检测系统可能没有充分准备或不适合。随着大流行似乎消退,并有望基于与 SARS-CoV-2 及其危害较小的变体共存而成为地方性环境,我们有理由认为,吸毒/贩毒动态也将恢复到大流行前的水平。制定旨在监测网络平台和社交媒体的政策,可能是控制新兴物质的宝贵工具,因为在 COVID-19 大流行期间,毒贩和买家之间的许多互动已经转移到了线上(14)。毕竟,社交媒体已经越来越多地成为互动平台,用户和毒品贩子可以利用这些平台来讨论毒品价格、物质纯度、他们正在寻找的“快感”(即所需的药物效果)的独特特征、服用物质的方式、剂量以及在这些后街营销渠道上提供的任何新 NPS 的特征(15)。专门设计和编程以筛选和分析有关方面所有可检测的在线信息的软件可能对了解不断变化的贩运、购买和使用动态很有价值。探测社交媒体用户已被证明是解决公共卫生问题的有效工具,例如毒品检测服务,由于其在估计有大量人群聚集的高风险地区的减少伤害潜力,已经被利用(音乐会、俱乐部等)。然而,需要将研究工作指向新的犯罪领域,即“暗网”,在那里众所周知,各种非法交流和互动都在进行。2020 年的一项研究强调了选择在暗网购买药物的药物使用者面临的惊人风险(16)。从一个特定的“暗网”市场上选择了三名毒贩,并通过这种渠道订购了 NPS。所有这些交易都被详细记录下来,并对因此购买的总共九种物质进行了分析,通过 NMR、HRMS、LC-UV 进行分析,其中三种还通过 x 射线衍射进行分析。最终得出的结论是,购买的五种物质中有四种被贴上了与实际物质不匹配的 NPS 名称,而被认为是新(即未列入名单)的三种 NPS 样本中的两种实际上是已经记录在案的物质,被错误标记并以虚假名义兜售。毒贩要么欺骗他们的客户,要么对他们正在销售的实际物质一无所知。鉴于这些极其令人担忧的发现,不难理解这种新的贩运和滥用趋势可能带来的影响和重大公共卫生风险。因此,科学界和执法机构有必要适应并努力应对新的毒品执法挑战,首先是“暗网”这个新的犯罪生态系统,该系统依赖于无法追踪的加密货币进行非法交易。